Olaparib, identified by its Chemical Abstracts Service (CAS) number 763113-22-0, represents a significant advancement in the field of oncology. This compound serves as the active pharmaceutical ingredient (API) in groundbreaking targeted therapies used to combat various forms of cancer. It is supplied as a high-quality, white or off-white crystalline powder, crucial for its downstream use in pharmaceutical formulations.

At its core, Olaparib functions as a potent inhibitor of Poly (ADP-ribose) polymerase (PARP) enzymes. These enzymes play a vital role in cellular DNA repair mechanisms. By blocking PARP, Olaparib prevents cancer cells, particularly those with existing DNA repair defects such as mutations in the BRCA1 or BRCA2 genes, from effectively repairing their damaged DNA. This leads to the accumulation of genetic errors, ultimately resulting in the death of cancer cells.

Clinical trials and regulatory approvals have established Olaparib's efficacy in treating specific patient populations across several cancer types. These include certain types of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, often in patients identified with relevant genetic mutations. Its targeted mechanism offers a more precise approach to therapy, potentially reducing side effects compared to traditional chemotherapy in selected individuals.

The production of high-quality pharmaceutical formulations relies fundamentally on the purity and consistency of the active pharmaceutical ingredient. For Olaparib API, stringent quality control measures are essential to ensure that it meets pharmacopoeial standards. Key parameters such as appearance, identification via techniques like IR and HPLC, solubility profiles, loss on drying, heavy metal content, residue on ignition, and residual solvent levels are rigorously tested. Related substances must also be kept below strict limits to guarantee the safety and efficacy of the final drug product. The material is provided in solid form, typically as a crystalline powder, requiring careful handling and storage in tight, light-resistant containers to maintain its integrity.

Ensuring a reliable supply chain for such a critical API is paramount for pharmaceutical manufacturers developing and producing Olaparib-based medicines. Companies seeking a reputable manufacturer and supplier of Olaparib API (CAS 763113-22-0) should prioritize partners demonstrating robust quality management systems and consistent production capacity. Information regarding the current price of Olaparib API can be obtained upon direct inquiry, reflecting market conditions and order volume. For those ready to buy or purchase this essential raw material, engaging with experienced suppliers simplifies the procurement process, ensuring timely delivery of material that complies with required specifications. This approach supports the continuous production of vital cancer treatments.